Mono PharmacareNSE:MONOPHARMA -1.79%9 Net Margin % is 0.03% as of Sep. 2025, which is 98% below its 10-year median of 1.84. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 62.35% on this metric.
The historical rank and industry rank for Mono Pharmacare's Net Margin % or its related term are showing as below:
NSE:MONOPHARMA'
s Net Margin % Range Over the Past 10 Years
Min: 0.34 Med: 1.84 Max: 2.11
Current: 0.56
NSE:MONOPHARMA's Net Margin % is ranked worse than 62.35% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 2.915
vs NSE:MONOPHARMA: 0.56
Mono Pharmacare (NSE:MONOPHARMA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Mono Pharmacare Net Margin % Related Terms
Mono Pharmacare Net Margin % Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare Net Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Net Margin % of 0.03% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Mono Pharmacare and its competitors. This is 98% below median its historical median of 1.84. Over the past decade, Mono Pharmacare's Net Margin % has ranged from 0.34 to 2.11. According to the industry distribution chart, Mono Pharmacare ranks #414 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 62.3%.
Is Mono Pharmacare's Net Margin % too high?
Mono Pharmacare's current Net Margin % of 0.03% is 98% below median its 10-year median of 1.84. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 2.11. The Healthcare Providers & Services industry median Net Margin % is 2.92. Mono Pharmacare's value of 0.03% is 99% below this industry median. Based on the distribution chart, Mono Pharmacare ranks #414 out of 664 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Net Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #414 out of 664 companies for Net Margin %. This places Mono Pharmacare in the lower half of its industry. The industry median Net Margin % is 2.92. Mono Pharmacare's value of 0.03% is 99% below this benchmark. Historically, Mono Pharmacare's own Net Margin % has ranged from 0.34 to 2.11 over the past decade. While the company's 10-year median is 1.84 vs. the industry median of 2.92, Mono Pharmacare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.92, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current Net Margin % of 0.03% is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current Net Margin % is 0.03%, which is 98% below median its own 10-year median of 1.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Net Margin % of 0.03%. The current Net Margin % is 0.03%, which is 98% below median its 10-year median of 1.84 and 99% below the Healthcare Providers & Services industry median of 2.92. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Net Margin % is 0.03% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
